Schulman Associates IRB, Inc., the industry-leading central IRB in customer service and technology, has announced board expertise and operational support to be based at its new office on Laboratory Drive in Research Triangle Park, Durham, North Carolina.

Last month, Schulman announced the signing of a long-term lease in Research Triangle Park, situating the IRB to better serve research organizations in the region’s life sciences community.

“We are very excited to be able to make this kind of commitment in the Triangle,” said Michael Woods, President, CEO and Institutional Official at Schulman. “We have already begun adding to our experienced team slated for this office. We will be bringing the highest level of service available in the IRB industry to customers based in North Carolina and beyond. Our RTP-based review board will bring significant expertise for institutions, Phase I research and device research to the Triangle research community.”

In addition to housing a review board at its new location, Schulman is adding additional resources in operations, IT, customer service and more.

Schulman expects to take occupancy of its office and for its staff to be fully operational later this summer.

About Schulman Associates IRB, Inc.

Schulman Associates IRB has been a leader in the protection of human research participants in the U.S., Puerto Rico and Canada since 1983. Schulman offers thorough, timely IRB review services – including dedicated review capabilities for all phases of research across all therapeutic areas – to clinical trial sponsors, CROs, investigators and institutions. Schulman also provides global consulting services through its joint venture partner Provision Research Compliance Services, offering comprehensive solutions to improve overall quality standards for clinical studies and data integrity, and to maximize the protection of human subjects. Fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), Schulman has an unparalleled clean audit history with the Food and Drug Administration (FDA).

For more information, please visit